Home' Trinidad and Tobago Guardian : January 24th 2015 Contents A28
body & soul
Guardian www.guardian.co.tt Saturday, January 24, 2015
MINISTRY OF FINANCE
INLAND REVENUE DIVISION
NOTICE TO ALL EMPLOYERS
T.D.4 SUPPLEMENTARY FORM
The Board of Inland Revenue wishes to advise that the 2014 T.D.4 Supplementary Forms
(Certificates) are available for preparation
as required under the PAYE Regulations.
These can be collected at the following locations:
THE TAXPAYER SERVICES SECTION
CORNER QUEEN AND EDWARD STREETS, PORT OF SPAIN
* SOUTH REGIONAL OFFICE
#52 CIPERO STREET, SAN FERNANDO
*ARIMA REGIONAL OFFICE
#6 PRINCE STREET, ARIMA
*INLAND REVENUE DIVISION
VICTOR E BRUCE, FINANCIAL COMPLEX, 14-16 WILSON ROAD,
and at the
*SANGRE GRANDE * POINT FORTIN
*TUNAPUNA * CHAGUANAS
DISTRICT REVENUE OFFICES
Request should be made in writing, on the Company's Letter head, stating the:
* Name and Address of the Organization, P.A.Y.E. Account Number and Board of
Inland Revenue [BIR] File Number and
* The Number of Employees for the period.
Annual Return of Remuneration Paid and Income Tax and Health Surcharge Deducted and
Remitted for 2014 (TD4 Summary Form) will be mailed to employers. These are to be com-
pleted and submitted together with the third copy of the TD4 Supplementary Form at any
Inland Revenue Regional Office. If one is not received, a request can be made in writing to
the above-mentioned Offices.
TAXPAYER RELATIONS SECTION
"Changing the way we interact with People!"
The first batch of an experimental vaccine
against Ebola is on its way to Liberia. The ship-
ment will be the first potentially preventative
medicine to reach one of the hardest hit countries.
But experts say that, with Ebola cases falling, it
may be difficult to establish whether the jab
offers any protection against the virus.
It has been produced by British company Glax-
oSmithKline (GSK) and the US National Institutes
of Health. GSK said a plane carrying some 300
initial doses of the vaccine was expected to arrive
in Monrovia on Friday. And the company hopes
the first volunteer will be immunised in the next
The chief executive of GSK, Sir Andrew Witty,
said the pace of development was almost unpar-
alleled and was comparable to only the develop-
ment of a pandemic flu vaccine or new medicines
He told the BBC: "As an example we have
delayed two other vaccine development pro-
grammes to free up the space to do this work, so
this has come with a significant amount of dis-
Scientists aim to involve 30,000 volunteers in
the trial in total, including frontline health workers.
If all regulations are met, 10,000 volunteers
will be given the GSK vaccine.
A matching number will get a placebo, dummy
vaccine. And there are plans for a further 10,000
people to get a separate experimental jab.
The results will be compared to see if either
vaccine offers any meaningful protection against
A version of the vaccine has already been tested
on 200 healthy volunteers across the UK, US,
Switzerland and Mali.
GSK says it has been found to have an acceptable
safety profile so far. But it is only in affected coun-
tries that experts can determine whether it provides
adequate protection against the virus.
Dr Moncef Slaoui, of GlaxoSmithKline said:
"Shipping the vaccine today is a major achievement
and shows that we remain on track with the accel-
erated development of our candidate Ebola vaccine.
"The initial phase one data we have seen are
encouraging and give us confidence to progress
to the next phases of clinical testing."
The company stresses the vaccine is still in
development and the World Health Organization,
and other regulators, would have to be satisfied
the vaccine is both safe and effective before any
mass immunisation campaigns could be consid-
Field trials of other promising vaccines---for
example one involving the company Merck---are
planned in Guinea, Liberia and Sierra Leone in
the months to come. And there are reports that
a trial of an experimental drug called Zmapp might
start in the next few weeks.
However, experts say with the number of Ebola
cases falling opportunities to test vaccines and
drugs could be limited.
Prof Jonathan Ball, a virus expert based at Not-
tingham University, told the BBC: "Because case
numbers are starting to come down it will become
harder and harder to show if the vaccine is having
"Ultimately we may be in position in a few
months time where we don t know whether this
vaccine is effective in humans.
"But it is important to get answers if we can---
if not for this outbreak, for future outbreaks. We
need to be prepared." (BBC)
A health official takes
temperature of a
soccer fan for Ebola
virus, ahead of the
Africa Cup of Nations
Group D soccer match
between Ivory Coast
and Guinea at the
Estadio De Malabo,
Equatorial Guinea on
moved to Equatorial
Guinea after Morocco
pulled out citing fears
about the spread of
Ebola. AP PHOTO
vaccine shipped to Liberia
YOUR DAILY HEALTH
News and Advice
"Because case numbers are
starting to come down it will
become harder and harder to
show if the vaccine (for Ebola) is
having any impact."
---Prof Jonathan Ball,
Links Archive January 23rd 2015 January 25th 2015 Navigation Previous Page Next Page